Novel therapies for the management of type 2 diabetes mellitus: Part 1. Pramlintide and bromocriptine-QR

Journal of Diabetes

Volumn 5, Issue 2, 2013, Pages 110-117

  Grunberger, George ^a  

^a Grunberger Diabetes Institute   (United States)

Author keywords

Antidiabetic drugs; Bromocriptine QR; Pramlintide

Indexed keywords

BROMOCRIPTINE; GLUCAGON; INSULIN; METFORMIN; PLACEBO; PRAMLINTIDE; SULFONYLUREA; TRIACYLGLYCEROL;

AMINO ACID SEQUENCE; ANOREXIA; ASTHENIA; CARDIOVASCULAR RISK; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DIZZINESS; DOPAMINERGIC TRANSMISSION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; FATIGUE; GLUCAGON RELEASE; GLUCONEOGENESIS; HUMAN; HYPOGLYCEMIA; HYPOINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE TRANSIT TIME; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; RHINITIS; RISK REDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; VOMITING;

BROMOCRIPTINE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; ISLET AMYLOID POLYPEPTIDE;

EID: 84877032712     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12034     Document Type: Review

References (46)

1. Moore CX, Cooper GJ. Co-secretion of amylin and insulin from cultured islet beta-cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun. 1991; 179: 1-9.
2. Wang F, Adrian TE, Westermark GT, Ding X, Gasslander T, Permert J. Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets. Am J Physiol. 1999; 276: E19-24.
3. Price CJ, Hoyda TD, Ferguson AV. The area postrema: Brain monitor and integrator of systemic autonomic state. Neuroscientist. 2008; 14: 182-194.
4. Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther. 2008; 2: 203-214.
5. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: Potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol. 2000; 278: G946-951.
6. Weyer C, Maggs DG, Young AA etal. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control. Curr Pharm Des. 2001; 7: 1353-1373.
7. Kong MF, King P, MacDonald IA etal. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia. 1997; 40: 82-88.
8. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002; 34: 504-508.
9. Fineman MS, Koda JE, Shen LZ etal. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002; 51: 636-641.
10. Chapman I, Parker B, Doran S etal. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005; 48: 838-848.
11. Smith SR, Blundell JE, Burns C etal. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: A 6-wk translational research study. Am J Physiol Endocrinol Metab. 2007; 293: E620-627.
12. Hoogwerf BJ, Doshi KB, Diab D. Pramlintide, the synthetic analogue of amylin: Physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag. 2008; 4: 355-362.
13. Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clin Diabetes. 2002; 20: 137-144.
14. Fineman M, Bahner A, Gottlieb A etal. Effects of six months of administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes. Diabetes. 1999; 48 (Suppl. 1): A113 (Abstract
15. Gottlieb A, Velte M, Fineman M etal. Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type1 diabetes during treatment for 52 weeks. Diabetes. 2000; 49 (Suppl. 1): A109 (Abstract
16. Whitehouse F, Kruger DF, Fineman M etal. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002; 25: 724-730.
17. Ratner RE, Dickey R, Fineman M etal. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: A 1-year, randomized controlled trial. Diabet Med. 2004; 21: 1204-1212.
18. Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG. Pramlintide, a synthetic analog of human amylin, improved the metabolic profile of patients with type 2 diabetes using insulin: The pramlintide in Type 2 Diabetes Group. Diabetes Care. 1998; 21: 987-993.
19. Gottlieb A, Fineman M, Bahner A. Pramlintide therapy in addition to insulin in type 2 diabetes: Effect on metabolic control after 6 months. Diabetologia. 2007; 42 (Suppl.): A232 (Abstract
20. Ratner R, Whitehouse F, Fineman MS etal. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes. 2005; 113: 199-204.
21. Hollander PA, Levy P, Fineman MS etal. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 2003; 26: 784-790.
22. Hollander P, Maggs DG, Ruggles JA etal. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004; 12: 661-668.
23. Kolterman OG, Gottlieb A, Moyses C, Colburn W. Reduction of postprandial hyperglycemic in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care. 1995; 18: 1179-1182.
24. Kolterman OG, Schwarz S, Corder C etal. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia. 1996; 39: 492-499.
25. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG. Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin and c-peptide concentrations in patients with type II diabetes. Diabet Med. 1997; 14: 547-555.
26. Heptulla RA, Rodriguez LM, Mason KJ, Haymond MW. Twenty-four-hour simultaneous subcutaneous basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia. J Clin Endocrinol Metab. 2009; 94: 1608-1611.
27. Huffman DM, McLean GW, Seagrove MA. Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: Observations from a pilot study. Endocr Pract. 2009; 15: 689-695.
28. Riddle M, Frias J, Zhang B etal. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007; 30: 2794-2799.
29. Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care. 2009; 32: 1577-1582.
30. Hirsch-Elkind K, Butler WJ, Bhushan M, Hirsch D, Bhushan R. Clinical experience with the addition of pramlintide in patients with insulin-requiring type 2 diabetes. Diabetes Care. 2008; 31: 39-40.
31. Herrmann K, Frias JP, Chen S, Miller S, Shan K, Maggs D. Pramlintide-induced shift towards euglycemia based on SMBG profiles in T2DM. Diabetes. 2012; 61 (Suppl. 1): A285 (Abstract
32. Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology. 1999; 70: 460-465.
33. Scranton R, Cincotta A. Bromocriptine: Unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010; 11: 269-279.
34. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 1996; 19: 667-670.
35. Kamath V, Jones CN, Yip JC etal. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care. 1997; 20: 1697-1701.
36. Cincotta AH, Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratusMetabolism. 1995; 44: 1349-1355.
37. Meier AH, Cincotta A. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev. 1996; 4: 464-487.
38. Pijl H, Ohashi S, Matsuda M etal. Bromocriptine: A novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000; 23: 1154-1161.
39. DeFronzo RA. Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011; 34: 789-794.
40. Schwartz S. Bromocriptine (Ergoset) improves glycemic control in type 2 diabetics on insulin. Diabetes. 1999; 48 (Suppl. 1): A99 (Abstract
41. Cincotta AH, Meier AH, Cincotta M Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: A new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999; 8: 1683-1707.
42. TM) improves glycaemic control in patients with diabetes failing metformin/sulfonylurea combination therapy. Diabetologia. 2008; 51: S372-373.
43. Gaziano JM, Cincotta AH, O'Connor CM etal. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010; 33: 1503-1508.
44. Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012; 1: e002279.
45. Florez H, Scranton R, Farwell WR etal. Randomized clinical trial assessing the efficacy and safety of bromocriptine-QR when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus. J Diabetes Metab. 2011; doi:10.4172/2155-6156.1000142.
46. Vinik AI, Cincotta AH, Scranton RE, Bohannon N, Ezrokhi M, Gaziano JM. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012; 18: 931-943.